[go: up one dir, main page]

MX2023012271A - Medicina terapeutica para enfermedades fibrosas. - Google Patents

Medicina terapeutica para enfermedades fibrosas.

Info

Publication number
MX2023012271A
MX2023012271A MX2023012271A MX2023012271A MX2023012271A MX 2023012271 A MX2023012271 A MX 2023012271A MX 2023012271 A MX2023012271 A MX 2023012271A MX 2023012271 A MX2023012271 A MX 2023012271A MX 2023012271 A MX2023012271 A MX 2023012271A
Authority
MX
Mexico
Prior art keywords
peptide fragment
hmgb1 peptide
specific
inventors
present
Prior art date
Application number
MX2023012271A
Other languages
English (en)
Inventor
Katsuto Tamai
Takehiko Yamazaki
Takahiro Aoto
Sho Yamazaki
Original Assignee
Stemrim Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stemrim Inc filed Critical Stemrim Inc
Publication of MX2023012271A publication Critical patent/MX2023012271A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Los presentes inventores descubrieron que un péptido de fragmento de HMGB1 que tiene una secuencia de aminoácidos particular muestra efectos de inhibir la adhesión de los dedos y la cicatrización del tracto digestivo y prolonga la supervivencia en los ratones modelo con epidermólisis ampulosa distrófica. También en el modelo de úlcera de la piel, la administración del péptido de fragmento de HMGB1 específico se encontró que inhibe la fibrosidad de la piel durante el proceso de cicatrización de la úlcera. Basado en estos descubrimientos, la presente solicitud proporciona composiciones farmacéuticas para el tratamiento de enfermedades fibróticas, que comprenden el péptido de fragmento de HMGB1 específico.
MX2023012271A 2017-04-07 2019-10-04 Medicina terapeutica para enfermedades fibrosas. MX2023012271A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2017076600 2017-04-07

Publications (1)

Publication Number Publication Date
MX2023012271A true MX2023012271A (es) 2023-10-24

Family

ID=63713333

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019012014A MX2019012014A (es) 2017-04-07 2018-04-06 Medicina terapeutica para enfermedades fibrosas.
MX2023012271A MX2023012271A (es) 2017-04-07 2019-10-04 Medicina terapeutica para enfermedades fibrosas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019012014A MX2019012014A (es) 2017-04-07 2018-04-06 Medicina terapeutica para enfermedades fibrosas.

Country Status (11)

Country Link
US (1) US20200038486A1 (es)
EP (1) EP3607963A4 (es)
JP (2) JPWO2018186480A1 (es)
KR (1) KR20190135519A (es)
CN (2) CN110621331A (es)
AU (1) AU2018250076A1 (es)
BR (1) BR112019020294A2 (es)
CA (1) CA3058877A1 (es)
MX (2) MX2019012014A (es)
RU (1) RU2019134382A (es)
WO (1) WO2018186480A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11969459B2 (en) 2017-01-27 2024-04-30 StemRIM Inc. Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure
JPWO2019107530A1 (ja) 2017-12-01 2020-11-26 株式会社ステムリム 炎症性腸疾患の治療薬
CN111868231B (zh) 2017-12-01 2024-05-31 斯特姆里姆有限公司 外胚层间充质干细胞及其产生方法
WO2019156137A1 (ja) 2018-02-08 2019-08-15 株式会社ステムリム 乾癬の治療薬
BR112021005982A2 (pt) * 2018-10-05 2021-06-29 StemRIM Inc. peptídeo possuindo atividade de mobilização de células-tronco mesenquimais
US12304933B2 (en) 2018-10-05 2025-05-20 StemRIM Inc. Disease treatment drug based on mesenchymal-stem-cell mobilization
KR20210082478A (ko) 2018-10-25 2021-07-05 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 연골 질환의 치료약
WO2020149395A1 (ja) * 2019-01-18 2020-07-23 国立大学法人大阪大学 栄養障害型表皮水疱症治療薬
CA3178719A1 (en) * 2020-04-03 2021-10-07 StemRIM Inc. Peptide having mesenchymal stem cell mobilizing activity
WO2023037562A1 (ja) * 2021-09-07 2023-03-16 国立大学法人大阪大学 肺炎の治療薬
JPWO2023053384A1 (es) * 2021-09-30 2023-04-06

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2631212A1 (en) * 2005-11-28 2007-07-05 Medimmune, Llc Antagonists of hmgb1 and/or rage and methods of use thereof
JP5865703B2 (ja) * 2009-10-28 2016-02-17 株式会社ジェノミックス 骨髄間葉系および／または多能性幹細胞の血中動員による組織再生促進剤
KR101992807B1 (ko) * 2011-04-26 2019-06-26 가부시키가이샤 스템림 조직 재생을 유도하기 위한 펩티드 및 그의 이용
SG11201503236RA (en) * 2012-10-25 2015-06-29 Genomix Co Ltd Novel method for treating cardiac infarction using hmgb1 fragment
GB201508337D0 (en) * 2015-05-15 2015-06-24 Hmgbiotech S R L Novel peptides
US11969459B2 (en) * 2017-01-27 2024-04-30 StemRIM Inc. Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure
CN111868231B (zh) * 2017-12-01 2024-05-31 斯特姆里姆有限公司 外胚层间充质干细胞及其产生方法

Also Published As

Publication number Publication date
US20200038486A1 (en) 2020-02-06
WO2018186480A1 (ja) 2018-10-11
MX2019012014A (es) 2019-11-11
RU2019134382A (ru) 2021-05-07
EP3607963A1 (en) 2020-02-12
EP3607963A4 (en) 2021-01-06
JPWO2018186480A1 (ja) 2020-02-20
AU2018250076A1 (en) 2019-10-31
CN117618534A (zh) 2024-03-01
CA3058877A1 (en) 2018-10-11
CN110621331A (zh) 2019-12-27
KR20190135519A (ko) 2019-12-06
RU2019134382A3 (es) 2021-08-13
BR112019020294A2 (pt) 2020-05-12
JP2023030070A (ja) 2023-03-07

Similar Documents

Publication Publication Date Title
MX2023012271A (es) Medicina terapeutica para enfermedades fibrosas.
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
MX2021002321A (es) Nuevos metodos.
MY198928A (en) B7-h3 antibody, antigen-binding fragment thereof and medical use thereof
SA520411119B1 (ar) تركيبات جسيم شحمي تشمل عقاقير مكونة من حمض ضعيف واستخداماتها
UA94734C2 (ru) ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ
MX2023010328A (es) Composiciones de medicamentos a base de peptido de colageno y metodos y dispositivos para su produccion y uso.
IN2015DN00376A (es)
EA201590166A1 (ru) Комбинированная терапия для лечения рассеянного склероза
PH12013500108A1 (en) Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
AR103896A1 (es) Conjugados de fármacos de anticuerpos (adc) anti-proteínas flt3
EP3747457A3 (en) Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases
NZ600544A (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
WO2016090024A3 (en) Combination therapy for treatment of cancer
SA521421371B1 (ar) لقاحات الببتيد
PH12017500392A1 (en) Medical treatments based on anamorelin
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
BR112017009986A2 (pt) métodos para tratar indivíduos com síndrome de prader-willi ou síndrome de smith-magenis
RU2017120184A (ru) Лекарства для замедления течения болезни паркинсона
MX2025001920A (es) Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina
HK1255584A1 (zh) 使用阿坎酸及d-环丝胺酸的联合疗法
EP4578461A3 (en) Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa
UA115250C2 (uk) Фармацевтичні комбінації
MX2017002476A (es) Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matriz extracelular.
MX2019008076A (es) Regimen terapeutico para el tratamiento de fabry usando alfa-galactosidasa estabilizada.